乌司他丁预防ERCP术后高淀粉酶血症及急性胰腺炎的临床研究

目的：观察乌司他丁预防ERCP术后高淀粉酶血症和急性胰腺炎的临床疗效。方法：73例ERCP术后患者随机分为治疗组（37例）和对照组（36例），均给予常规治疗；治疗组加用乌司他丁。观察两组患者ERCP术后出现高淀粉酶血症和急性胰腺炎例数，血清淀粉酶水平的变化．血淀粉酶恢复正常和临床症状缓解时间。结果：治疗组患者术后高淀粉酶血症或急性胰腺炎的发生例数明显少于对照组，血清淀粉酶上升幅度明显低于对照组（P〈0．05）．血淀粉酶水平恢复正常和临床症状缓解时间较对照组缩明显短（P〈0．05）。结论：乌司他丁能减少ERCP术后高淀粉酶血症及急性胰腺炎的发生．加快血淀粉酶恢复和临床症状的缓解。

Clinical Investigation of Ulinastatin in Preventing and Treating Hyperamylasemia and Acute Pancreatitis Following Endoscopic Retrograde Cholangio Pancreatography

Objective： To observe the clinical effects of ulinastatin in the prevention and treatment of hyperamylasemia and acute pancreatitis tbllowing endoscopic retrograde cholangio pancreatography （ERCP）. Methods：73 post ERCP patients were randomized into two groups： treatment group in which 37 cases were treated with routine therapy plus ulinastatin and control group in which 36 cases were treated with only routine therapy. The numbers of the onset of hyperamylasemia and acute pancreatitis were observed. The level of serum amylase, and the time of serum amylase restoration to normal and clinical symptoms relief were also observed. Results： The hyperamylasemia and acute pancreatitis happened less frequently in treatment group than in control group. The increasing extent of serum amylase in the treatment group was significant less than that in control group （P〈0.05）. The time of clinical symptoms relief and the restoration of blood amylase to normal was shorter in treatment group than in control group （P〈0.05）. Conclusion： Ulinastatin can reduce the onset of hyperamylasemia and acute pancreatitis following ERCP and accelerate the restoration of blood amylase and clinical symptoms relief.